What is Insulet's cash & equivalents?

Insulet (PODD) reported cash & equivalents of $480.4M in Q1 2026.

How has Insulet's cash & equivalents changed year-over-year?

Insulet's cash & equivalents decreased by 62.6% year-over-year, from $1.28B to $480.4M.

What is the long-term trend for Insulet's cash & equivalents?

Over 5 years (2020 to 2025), Insulet's cash & equivalents has grown at a -4.9% compound annual growth rate (CAGR), from $922M to $716.1M.

Insulet PODD Cash & Equivalents

Cash & Equivalents at other companies

Eli LillyLLY

$5.28B+70.8%

MedtronicMDT

$1.95B-12.1%

West Pharmaceutical ServicesWST

$521.4M+29.0%

AbbottABT

$6.8B+4.1%

ViatrisVTRS

$1.81B+139%

Other financials

Income statement

See full

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

See full

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

See full

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Free cash flow$89.5M+73.8%

Valuation

See full

Market cap$10.1B-19.9%

Enterprise value$10.59B-19.4%

P/E33.3×+2.0×

P/S3.5×-2.3×

Profitability

See full

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

See full

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insulet's cash & equivalents?: Insulet (PODD) reported cash & equivalents of $480.4M in Q1 2026.
How has Insulet's cash & equivalents changed year-over-year?: Insulet's cash & equivalents decreased by 62.6% year-over-year, from $1.28B to $480.4M.
What is the long-term trend for Insulet's cash & equivalents?: Over 5 years (2020 to 2025), Insulet's cash & equivalents has grown at a -4.9% compound annual growth rate (CAGR), from $922M to $716.1M.